Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–572 of 572 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-alcoholic Steatohepatitis (NASH) Clear all
Not listed No phase listed Observational

Development of Kinetic Biomarkers of Liver Fibrosis Measuring NAFLD

NCT02124577
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 14, 2026, 10:34 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
IVA337, Placebo
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
194
States / cities
Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

NCT05415722
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
TERN-501, TERN-101, Placebo
Drug · Other
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
35
States / cities
Chandler, Arizona • Tucson, Arizona • Coronado, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Not applicable Interventional

The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology

NCT05370053
View directory record Official record
Conditions
Fatty Liver, NAFLD
Interventions
ELF Test
Diagnostic Test
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Not applicable Interventional

Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects

NCT04285554
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
iRF System Hepatic Denervation
Device
Lead sponsor
Metavention
Industry
Eligibility
22 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Birmingham, Alabama • Stanford, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 14, 2026, 10:34 AM EDT
Recruiting No phase listed Observational

Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis

NCT05720663
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Standard of care
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Not listed Not applicable Interventional

Hepaxa Management of Non-alcoholic Fatty Liver Disease

NCT03801577
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, NASH - Nonalcoholic Steatohepatitis
Interventions
Hepaxa
Dietary Supplement
Lead sponsor
BASF AS
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Flowood, Mississippi
Source: ClinicalTrials.gov public record
Updated Jan 11, 2019 · Synced Oct 14, 2026, 10:34 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

NCT04048876
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Liver Cirrhosis
Interventions
CC-90001, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
64
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease

NCT03998514
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
CB4211 Dose 1, CB4211 Dose 2, CB4211 Dose 3, CB4211 Dose 4, CB4211 Dose 5, CB4211 Dose 6, CB4211 Dose TBD, Placebo
Drug
Lead sponsor
CohBar, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
4
States / cities
Chula Vista, California • Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Not applicable Interventional

YMCA Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)

NCT03512184
View directory record Official record
Conditions
Weight Loss, NAFLD, Liver Diseases
Interventions
YMCA class
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 14, 2026, 10:34 AM EDT
Recruiting Not applicable Interventional

The Olmsted NAFLD Epidemiology Study (TONES)

NCT04365855
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Interventions
Magnetic Resonance Elastography, Blood draw, Liver biopsy, Fibro Scan
Diagnostic Test · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Not applicable Interventional

A Phase II Study of the Effect of a Low Calorie Diet on Patients Undergoing Liver Resection

NCT01645852
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Hepatic Steatosis, Steatohepatitis
Interventions
Optifast 800
Dietary Supplement
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Worcester, Massachusetts • Lebanon, New Hampshire • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3

NCT02466516
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis (NASH)
Interventions
SEL, SIM
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
26
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Determination of the Effect of Extreme Dietary Carbohydrate Restriction on Hepatic Glucose Production

NCT01262326
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Calorie and Carbohydrate Restriction
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients

NCT01811472
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
LCQ908, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
11
States / cities
Mobile, Alabama • San Diego, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)

NCT04618744
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
Interventions
ORMD-0801 (Insulin) capsule 8 mg BD, Placebo
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 14, 2026, 10:34 AM EDT
Active, not recruiting No phase listed Observational

Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV

NCT04795219
View directory record Official record
Conditions
NAFLD, NAFLD-HIV, Hiv
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
8
States / cities
Tuscaloosa, Alabama • La Jolla, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis

NCT02510599
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
solithromycin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 14, 2026, 10:34 AM EDT
Withdrawn No phase listed Observational

Assessment of Fatty Liver With Thermo-acoustic Device

NCT04302051
View directory record Official record
Conditions
NASH, NAFLD, Non-alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Fatty Liver, Fatty Liver Disease
Interventions
Thermo-acuostic image acquisition of liver, MRI-PDFF estimation of hepatic fat
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Enrolling by invitation No phase listed Observational

Short and Long Term Clinical and Patient-Reported Outcomes Associated With Intragastric Balloon Placement in Patients With Nonalcoholic Fatty Liver Disease

NCT07493967
View directory record Official record
Conditions
NAFLD
Interventions
Not listed
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 14, 2026, 10:34 AM EDT